Key facts
- This page summarizes Ralph Niven's Form 4 filing for Aerovate Therapeutics, Inc. (JBIO).
- 8 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 07 Feb 2024, 18:00.
Ralph Niven - 05 Feb 2024 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)
- Reporting relationship
- CHIEF SCIENTIFIC OFFICER
- Issuer ticker
- JBIO
- Reported as of
- 05 Feb 2024
- Net transaction value
- -$70,965
- SEC form
- 4
- Accepted by SEC
- 07 Feb 2024, 18:00:11 UTC
- Prior SEC filing
- 24 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ George A. Eldridge, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ralph Niven filed Form 4 for Aerovate Therapeutics, Inc. (JBIO) on 07 Feb 2024.
Change
- Previous filing in this sequence was filed on 24 Jan 2024.
- Current net transaction value: -$70,965.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AVTE
transaction
Common Stock
Options Exercise
- Transaction value
- $2,436
- Shares
- +1,400
- Change %
- +87%
- Price
- $1.74*
- Shares after
- 3,009
- Date
- 05 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
AVTE
transaction
Common Stock
Options Exercise
- Transaction value
- $6,848
- Shares
- +3,200
- Change %
- +106%
- Price
- $2.14*
- Shares after
- 6,209
- Date
- 05 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
AVTE
transaction
Common Stock
Sale
- Transaction value
- $80,249
- Shares
- -4,600
- Change %
- -74%
- Price
- $17.45
- Shares after
- 1,609
- Date
- 05 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVTE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -900
- Change %
- -6.3%
- Price
- $0.000000
- Shares after
- 13,308
- Date
- 05 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 900
- Exercise price
- $1.74
- Footnotes
- F1, F3
AVTE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -500
- Change %
- -5.2%
- Price
- $0.000000
- Shares after
- 9,088
- Date
- 05 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 500
- Exercise price
- $1.74
- Footnotes
- F1, F4
AVTE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -500
- Change %
- -4.4%
- Price
- $0.000000
- Shares after
- 10,894
- Date
- 05 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 500
- Exercise price
- $2.14
- Footnotes
- F1, F5
AVTE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,200
- Change %
- -3.3%
- Price
- $0.000000
- Shares after
- 34,908
- Date
- 05 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,200
- Exercise price
- $2.14
- Footnotes
- F1, F6
AVTE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -1,500
- Change %
- -3.5%
- Price
- $0.000000
- Shares after
- 41,732
- Date
- 05 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,500
- Exercise price
- $2.14
- Footnotes
- F1, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 7 footnotes
Footnote F1
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.
Footnote F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.16 to $18.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Footnote F3
A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
Footnote F4
A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
Footnote F5
A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021.
Footnote F6
A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.
Footnote F7
A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.